18.34 USD
↗ 0.55 (3.09%)AT CLOSE (11:59 AM EDT)
MoonLake Immunotherapeutics Class A Ordinary Shares
MLTXNASDAQ • USD
18.30
↘ 0.04 (0.22%)
POST MARKET (AS OF 07:59 PM EDT)
Post Market
AS OF 07:59 PM EDT
18.30
↘ 0.04 (0.22%)
Market: CLOSED
Open?$18.30
High?$18.57
Low?$18.13
Prev. Close?$17.79
Volume?858.4K
Avg. Volume?1.2M
VWAP?$18.38
Rel. Volume?0.74x
Bid / Ask
Bid?$15.72 × 100
Ask?$20.87 × 100
Spread?$5.15
Midpoint?$18.30
Valuation & Ratios
Market Cap?1.3B
Shares Out?71.7M
Float?43.9M
Float %?61.3%
P/E Ratio?N/A
P/B Ratio?4.32
EPS?-$3.15
Dividend?0.00%
Ex-Dividend?N/A
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?9.27Strong
Quick Ratio?9.27Strong
Cash Ratio?7.36Strong
Debt/Equity?0.24Low
ValuationATTRACTIVELY VALUED
Score83/100
P/E?N/A▾
P/B?4.32FAIR▾
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?-4.4CHEAP▾
EV/Sales?N/A▾
Returns & Efficiency
ROE?-74.2%WEAK▾
ROA?-53.2%WEAK▾
Cash Flow & Enterprise
FCF?$-196042000
Enterprise Value?$1.1B
News
Profile
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.
Employees
130
Market Cap
1.3B
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2022-04-06
Address
DORFSTRASSE 29
ZUG, V8 6300
Phone: 41 41 510 8022
ZUG, V8 6300
Phone: 41 41 510 8022